Yasin Şakir GÖKER, Kemal TEKİN, Hasan KIZILTOPRAK, Cemile ÜÇGÜL ATILGAN, Pınar KÖSEKAHYA

Diyabetik Makula Ödeminde Bevacizumab Tedavisi: Gerçek Bir Yaşam Çalışması

Amaç: Bu çalışmada diyabetik makula ödemi (DMÖ) tedavisinde intravitreal bevacizumab (IVB) kullanımının 2 yıllık sonuçlarını bir geçek yaşam çalışması olarak sunulmuştur. Yöntemler: Bu retrospektif çalışmaya DMÖ nedeniyle 3 yükleme dozunun ardından pro-re-nata rejimi dahilinde IVB enjeksiyonu yapılan hastaların iki yıllık sonuçları dahil edildi. Hastaların Snellen eşeline göre en iyi düzeltilmiş görme keskinlikleri (EİDGK), göz içi basınçları ve ön ve arka segment bulguları incelendi. Tüm olguların 1. ve 2. yıldaki toplam enjeksiyon ve vizit sayıları, üç yükleme dozunun tamamlanma süresi, merkezi makula kalınlığı (MMK) ve EİDGK'deki 3'er ay ara olan değişiklikler değerlendirildi. Bulgular: Çalışma kapsamında 19 hastanın (8 erkek, 11 kadın) 28 gözü incelendi. Ortalama yaş 60,57 ± 9,58 (41-79) yıl olarak bulundu. Ortalama başlangıç EİDGK 0,37 ± 0,25 olarak bulundu ve üç yükleme dozunu takiben 0,51 ± 0,30'a ilerledi (p=0,003). Üç yükleme dozunun tamamlanma süresinin 89,71 ± 17,24 (61-105) gün olduğu görüldü. 6. ayda ve 12. aydaki EİDGK sırasıyla 0,58 ± 0,30 ve 0,50 ± 0,29 (sırasıyla p=0,001 ve p=0,006) olarak izlendi. İlk yılda ortalama enjeksiyon sayısının 6,1 ± 1,91 (3-9); toplam vizit sayısının ise 8,26 ± 1,99 (5-12) olduğu görüldü. 18. aydaki ve 24. aydaki EİDGK sırasıyla 0,46 ± 0,31 ve 0,50 ± 0,29 (sırasıyla p=0,046 ve p=0,038) olarak izlendi. Ortalama başlangıç MMK 398,48 ± 43,59 (341-494) mikron olarak bulundu ve birinci ve ikinci yılın sonunda sırasıyla 361,73 ± 54,40 (268-476) ve 322,93 ± 50,69 (220-414) mikrona ilerledi. (sırasıyla p=0,003 ve p

Bevacizumab Therapy For Diabetic Macular Edema: A Real Life Study

Objective: In this study, two-year results of the intravitreal bevacizumab in the treatment of diabetic macular edema (DME) were presented as a real-life experience. Methods: This retrospective study included two year results of the patients who underwent IVB injections within the pro-re-nata protocol following 3 loading doses owing to DME. The best corrected visual acuities (BCVAs) according to the Snellen chart, intraocular pressures, and anterior and posterior segment findings were recorded. All participants were evaluated according to their total number of injections and visits at 1. and 2. years, completion time of three loading doses, changes in central macular thicknesses (CMT) and BCVAs over the course of 3 months. Results: Twenty-eight eyes of 19 patients (8 male, 11 female) were analyzed. The mean age was 60,57 ± 9,58 (41-79) years. The mean baseline BCVA was 0.37 ± 0.25 and increased to 0,51 ± 0,30 following three loading doses (p=0.003). It was observed that the completion time of the three loading doses was 89,71 ± 17,24 (61-105) days. At the 6th month and 12th month, the BCVAs were 0,58 ± 0,30 and 0,50 ± 0,29 respectively (p=0,001 and p=0,006, respectively). The mean number of injections in the first year was 6.1 ± 1.91 (3-9); and the total number of the visits was 8.26 ± 1.99 (5-12). The BCVAs at the 18th and 24th months were 0,46 ± 0,31 and 0,50 ± 0,29 respectively (p=0,046 and p=0,038, respectively). The mean baseline CMT was 398,48 ± 43,59 (341-494) microns and improved to 361,73 ± 54,40 (268- 476) and 322,93 ± 50,69 (220-414) microns at the end of the first and the second year respectively (p=0,003 and p

PDF

___

1. Yau JWY, Rogers SL, Kawasaki R, et all. Meta-Analysis for Eye Disease (META-EYE) Study Group: Global prevalence and risk factors of diabetic retinopathy. Diabetes Care. 2012; 35: 556–64.
2. Bali J, Bali RT: Pathological ocular angiogenesis in diabetes: a perspective of emerging paradigms and current evidence. J Clin Ophthalmol Res. 2013; 1: 3–10.
3. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306– 9.
4. Ishida S, Usui T, Yamashiro K, et all. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003; 44: 2155–62.
5. Keck PJ, Hauser SD, Krivi G, et all. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989; 246: 1309–12.
6. Yang JC, Haworth L, Sherry RM, et all. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427–34.
7. Marshall J. The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol. 2005; 32: 43–7.
8. Michaelides M, Kaines A, Hamilton RD, et all: A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010; 117: 1078–1086.e2.
9. Arevalo JF, Liu TYA; Pan-American Collaborative Retina Study Group (PACORES). Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture. Asia Pac J Ophthalmol (Phila). 2018; 7: 36-9.
10. Ziemssen F, Lüke M, Messias A, et all. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol. 2008; 28: 101-9.
11. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 270–4.
12. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257–261.
13. Haritoglou C, Kook D, Neubauer A, et all. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006; 26: 999–1005.
14. Arevalo JF, Fromow-Guerra J, Quiroz-Marcado H, et all. Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007; 114: 743–50.
15. Yanyali A, Aytug B, Horozoglu F, Nohucu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007; 144: 124–6.
16. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, et all: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372: 1193–203.
17. Ross EL, Hutton DW, Stein JD, et all. Costeffectiveness of Aflibercept, Bevacizumab, and Ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016; 134: 888–96.
18. Elman MJ, Ayala A, Bressler NM, et all. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015; 122: 375–81.
19. Mitchell P, Bandello F, Schmidt-Erfurth U, et all; RESTORE Study Group: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118: 615–625.
20. Brand C, Mitchell P, Parikh S, Lacey S: Real world outcomes at 1 year with ranibizumab 0.5 mg in diabetic macular edema patients with low baseline visual acuity: results from the third interim analysis of LUMINOUS study. Presented at the 16th EURETINA Congress, Copenhagen, 2016.
21. Arevalo JF, Lasave AF, Wu L, et all; Pan-American Collaborative Retina Study Group (PACORES): Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group. Br J Ophthalmol. 2016; 100: 1605– 10.